Invited to the Table, But Not Enabled to Be There

Patient advocacy should not mean unpaid, unsupported participation

There is another uncomfortable dimension to this conversation.

In many mature healthcare and research ecosystems globally, patient engagement is increasingly recognised as a professional contribution, not merely voluntary goodwill. Patient advocates participating in conferences, advisory boards, policy consultations, research initiatives and industry discussions may receive appropriate support for travel, accommodation and other participation-related expenses – and, where the nature of the engagement warrants it, honoraria for their time, expertise and contribution.

The principle is simple:

Lived experience has value.

A patient advocate is not simply a person who happens to have had cancer. They may bring years of experience navigating treatment, healthcare systems, clinical research, financial toxicity, quality-of-life issues and the realities faced by patients and caregivers.

That expertise deserves recognition.

In India, however, we still have a long way to go.

Patient voices are too often treated as an add-on, a symbolic presence or a formality rather than as an essential stakeholder voice. Patients may be invited to a panel, given a few minutes to speak or included in a photograph – but meaningful participation, representation and support are still far from being the norm.

And this creates a paradox.

We say we want patient-centric healthcare, but the patient is often the least empowered participant in the room.

We talk about equity, while the person representing lived experience may have to personally absorb the cost of travelling hundreds or thousands of kilometres to participate.

We talk about valuing patient voice, while expecting that voice to be provided entirely on a voluntary basis, even when other stakeholders are participating as professionals representing well-resourced institutions.

We need to ask ourselves honestly:

Are we inviting patients because we genuinely value what they bring – or because patient inclusion has become something we feel we are expected to demonstrate?

There is a difference between patient presence and patient participation.

And there is an even bigger difference between participation and meaningful influence.

India’s patient advocacy ecosystem is evolving rapidly, and there are certainly organisations, researchers, clinicians, policymakers and industry leaders who are doing this well. But these examples need to become the norm rather than the exception.

Patient advocates should not have to repeatedly justify why their travel needs to be supported.

They should not have to prove that their time has value.

And they should not have to choose between contributing to healthcare policy and personally bearing costs that other stakeholders would ordinarily not be expected to bear.

If we genuinely believe that nothing about patients should be decided without patients, then we must also create the practical conditions that allow patients to be present, heard and respected.

Patient inclusion cannot remain a showpiece. It has to become a standard.

Why Speaking Up for India and LMICs in Global Healthcare is Non-Negotiable

I recently had the privilege of representing India at a global advisory board meeting for lung cancer. These meetings are vital for shaping the future of oncology, yet a familiar pattern emerged: the discussion on “access” was almost entirely dominated by the landscapes of the US and the European Union.

While the challenges in those regions are real, “access” takes on a completely different meaning in India and other developing nations. In our context, it isn’t just about administrative hurdles; it’s about the fundamental availability of life-saving innovation for millions who are often left out of the global conversation.

The Power of the “Living Experience”

During the sessions, I made it a point to politely but firmly steer the conversation toward the missing voices of India and LMICs. It is easy for global boards to view these regions as “emerging markets,” but the reality is that we are the global hotspots for lung cancer. If we can solve the access puzzle in India, we can solve it anywhere.

I was heartened to see this message resonate. Shortly after the meeting, a senior colleague and representative from Australia shared his takeaways on LinkedIn, specifically highlighting that developing nations in Asia Pacific and India must continue to stand up to be heard.

Why Your Voice Matters

This experience reminded me of three critical truths for advocates:

  • Visibility is the first step to Access: If we aren’t at the table – or if we stay silent while at the table – the world will continue to design solutions that don’t fit our reality.
  • Data + Experience = Impact: Combining Health Technology Assessment (HTA) with the “living experience” of patients creates a narrative that even the most complex geopolitical or economic systems cannot overlook.
  • The Ripple Effect: When you speak up, you aren’t just influencing the person across from you. You are providing the language and the courage for other leaders to carry that message back to their own countries.

Moving Forward

Advocacy is often a long, uphill climb, but seeing the immediate impact of a single intervention at a global meeting is a powerful motivator. We must continue to demand that the global oncology conversation reflects the global reality.

Our voices are not just “participation” – they are the essential evidence required to build a more equitable healthcare future.

No One Should Fight Alone!

Vivek